SCHEMBL233744

SCHEMBL233744

OCCc1c[nH]c2ccc(O)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 6/20 1.00
CYP2D6 P10635 5/20 0.73
HTR1A P08908 4/20 0.73
HTR2A P28223 4/20 0.73
HTR1D P28221 4/20 0.73
HTR2B P41595 3/20 0.73
CYP2C9 P11712 3/20 0.73
CYP1A2 P05177 3/20 0.73
TSHR P16473 2/20 0.73
CYP3A4 P08684 2/20 0.73
HTR1B P28222 2/20 0.73
HTR3E A5X5Y0 1/20 0.73
HTR3B O95264 1/20 0.73
DRD1 P21728 1/20 0.73
HTR1E P28566 1/20 0.73
HTR1F P30939 1/20 0.73
HTR7 P34969 1/20 0.73
DRD3 P35462 1/20 0.73
RECQL P46063 1/20 0.73
HTR3A P46098 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29351067 1.00 HTR2C (1.00) HTR2CCYP2D6HTR1AHTR2AHTR1D
SCHEMBL7002494 0.87 HTR2C (0.77) HTR2CCYP2D6HTR1AHTR2AHTR1D
SCHEMBL21132337 0.86 HTR2C (0.75) HTR2CCYP2D6HTR1AHTR2AHTR1D
SCHEMBL28534064 0.85 HTR2C (0.74) HTR2CCYP2D6HTR1AHTR2AHTR1D
Serotonin SCHEMBL29349412 0.84 HTR2C (1.00) HTR2CCYP2D6HTR1AHTR2AHTR1D
SCHEMBL10871259 0.84 HTR2C (0.73) HTR2CCYP2D6HTR1AHTR2AHTR1D
Serotonin SCHEMBL1495 0.84 HTR2C (1.00) HTR2CCYP2D6HTR1AHTR2AHTR1D
Serotonin SCHEMBL30057954 0.84 HTR2C (1.00) HTR2CCYP2D6HTR1AHTR2AHTR1D
SCHEMBL18618253 0.84 HTR2C (0.73) HTR2CCYP2D6HTR1AHTR2AHTR1D
SCHEMBL6986225 0.84 HTR1D (0.73) HTR2CCYP2D6HTR1AHTR2AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118480173-B Cationic polyester and preparation method and application thereof 深圳市信必递生物科技有限公司 2025-02-07 CN claimed
CN-118480173-A Cationic polyester and preparation method and application thereof 深圳市信必递生物科技有限公司 2024-08-13 CN claimed
CN-115701440-A Polyimide composite film, preparation method thereof and electronic equipment 华为技术有限公司 2023-02-10 CN claimed
US-10175258-B2 Detection of synthetic cannabinoids RANDOX LABORATORIES LIMITED (GB) 2019-01-08 US claimed
WO-2017189528-A1 CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME Ecolab USA, Inc. (US) 2017-11-02 WO claimed
US-20170306504-A1 CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME CHAMPIONX LLC 2017-10-26 US claimed
US-20150118763-A1 DETECTION OF SYNTHETIC CANNABINOIDS RANDOX LABORATORIES LIMITED (GB) 2015-04-30 US claimed
US-8906633-B2 Detection of synthetic cannabinoids RANDOX LABORATORIES LIMITED (GB) 2014-12-09 US claimed
EP-2344114-A2 HAIR CARE COMPOSITIONS, METHODS, AND ARTICLES OF COMMERCE THAT CAN INCREASE THE APPEARANCE OF THICKER AND FULLER HAIR The Procter & Gamble Company (US) 2011-07-20 EP claimed
WO-2010054343-A2 HAIR CARE COMPOSITIONS, METHODS, AND ARTICLES OF COMMERCE THAT CAN INCREASE THE APPEARANCE OF THICKER AND FULLER HAIR THE PROCTER & GAMBLE COMPANY (US) 2010-05-14 WO claimed
WO-1998024819-A1 5-HYDROXYTRYPTOPHOL (5-HTOL) DERIVATIVES, ANTIBODIES, IMMUNOASSAYS AND DETECTION OF RECENT ALCOHOL CONSUMPTION AXIS BIOCHEMICALS ASA (NO) 1998-06-11 WO claimed
EP-0566566-B1 COMPOSITIONS AND METHODS FOR ALLEVIATING MENOPAUSAL SYMPTOMS APPLIED MED RES LTD (US) 1995-12-06 EP claimed
EP-0566566-A1 COMPOSITIONS AND METHODS FOR ALLEVIATING MENOPAUSAL SYMPTOMS. APPLIED MED RES LTD (US) 1993-10-27 EP claimed
EP-0415802-B1 KERATINOUS FIBRES DYEING PROCESS WITH MONOHYDROXYINDOLE AND HYDROXYINDOLE-5,6-DISUBSTITUTED AND COMPOSITION L'OREAL (FR) 1993-03-10 EP claimed
EP-0271186-B1 HYDROXYINDOLES AND THEIR USE IN DYEING REPLIGEN CORPORATION (US) 1992-12-30 EP claimed
US-5135544-A Applying indole mixture, rinsing, applying periodate solution L'OREAL (FR) 1992-08-04 US claimed
WO-1992011855-A1 COMPOSITIONS AND METHODS FOR ALLEVIATING MENOPAUSAL SYMPTOMS APPLIED MEDICAL RESEARCH, LTD. (US) 1992-07-23 WO claimed
EP-0472628-A1 USE OF MELATONIN DERIVATIVES FOR EFFECTING CONTRACEPTION APPLIED MEDICAL RESEARCH, LTD. (US) 1992-03-04 EP claimed
EP-0415802-A1 Keratinous fibres dyeing process with monohydroxyindole and hydroxyindole-5,6-disubstituted and composition L'OREAL (FR) 1991-03-06 EP claimed
WO-1990014084-A1 USE OF MELATONIN DERIVATIVES FOR EFFECTING CONTRACEPTION COHEN MICHAEL (NL) 1990-11-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150118763-A1 DETECTION OF SYNTHETIC CANNABINOIDS CNR2, CNR1, FAAH HTR2C 831/4885CYP2D6 1679/4885HTR1A 980/4885
US-10175258-B2 Detection of synthetic cannabinoids CNR2, CNR1, FAAH HTR2C 831/4885CYP2D6 1679/4885HTR1A 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.